Astellas Pharma Branches Out In U.S., Offers Career-building Workshops To Employees
This article was originally published in PharmAsia News
Executive Summary
With the national unemployment rate hitting 8.5 percent in March, the highest in 25 years, many U.S. pharmaceutical companies - once considered to have relatively strong cash reserves and traditionally immune to economic recessions - have begun slashing payrolls and announcing tens of thousands of layoffs
You may also be interested in...
Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
Usually, having more money that you know how to use is not considered a problem, but cash-rich Astellas may feel a bit stranded now that Gilead has trumped its bid to buy CV Therapeutics. But at least one analyst thinks the U.S. biotech sector still offers plenty of potential acquisitions for the Japanese pharma
Takeda’s Bid For Millennium May Face Several Hurdles – Pharma Analyst
TOKYO - Several factors could still prevent Japan's top drug company Takeda from acquiring U.S.-based Millennium Pharmaceuticals, a pharmaceutical analyst said in an interview with PharmAsia News
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10